Open Access
CC BY 4.0 · Journal of Digestive Endoscopy
DOI: 10.1055/s-0045-1810606
Original Article

Clinical Outcomes and Predictors of Early Adverse Events in Primary EUS-Guided Choledochoduodenostomy for Malignant Distal Biliary Obstruction

Authors

  • Nozomi Okuno

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Kazuo Hara

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Shin Haba

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Takamichi Kuwahara

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Hiroki Koda

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Shimpei Matsumoto

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Keigo Ooshiro

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Tomoki Ogata

    1   Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
Preview

Abstract

Background and Aim

Endoscopic ultrasound-guided biliary drainage (EUS-BD) is an alternative for failed endoscopic retrograde cholangiopancreatography, with increasing reports of its use as primary drainage. We have performed primary EUS-guided choledochoduodenostomy (EUS-CDS) since 2010, continuously improving techniques for safety. This study evaluated factors influencing early adverse events.

Materials and Methods

Of 306 consecutive patients in whom EUS-CDS was attempted between September 2003 and February 2025, we conducted a retrospective study of 190 in whom primary EUS-CDS was attempted using a covered self-expandable metal stent for malignant distal biliary obstruction.

Results

EUS-CDS was deemed unsuitable in 26 of 190 cases (13.7%) due to ascites or tumor invasion, and the procedure was aborted without puncture. Among eligible cases, the technical and clinical success rates were 97.0% (159/164) and 97.5% (155/159), respectively. Early adverse events occurred in 4.9% (8/164), including acute cholangitis/peritonitis/mucosal double penetration/acute cholecystitis/bleeding (3/2/2/2/2) (overlap) with one severe case. Multivariate analysis identified scope type (OR: 5.153, 95% CI: 1.15–22.92, p = 0.031) as an independent risk factor for early adverse events.

Conclusion

Primary EUS-CDS demonstrated high technical and clinical success rates with a low early adverse event rate. Scope type was an independent risk factor. Proper patient selection and device modifications can enhance the safety and feasibility of primary EUS-CDS.



Publikationsverlauf

Artikel online veröffentlicht:
08. August 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India